<DOC>
	<DOCNO>NCT00360490</DOCNO>
	<brief_summary>The purpose study determine whether levonorgestrel-releasing intrauterine system effective decrease menstrual blood loss .</brief_summary>
	<brief_title>Study Women With Idiopathic Menorrhagia Determine Reduction Menstrual Blood Loss ( MBL ) After Treatment With Levonorgestrel-releasing Intrauterine System ( IUS )</brief_title>
	<detailed_description>Acronyms Adverse Event Section : - IUCD Intrauterine Contraceptive Device - MedDRA Medical Dictionary Regulatory Activities This study previously post Berlex , Inc. Schering AG , Germany . Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. , Schering AG Germany rename Bayer HealthCare AG , Germany .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Women &gt; /= 80 mL blood loss menstrual cycle desire contraception Post menopausal menstrual cycle &lt; 21 day &gt; 35 day Pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Idiopathic Menorrhagia</keyword>
</DOC>